Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Robert Bast

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Anatomy

Chemicals & Drugs

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kurzrock Razelle; Pilat Susan; Bartolazzi Marcel; Sanders Dwana; Van Wart Hood Jill; Tucker Stanley D; Webster Kevin; Mallamaci Michael A; Strand Steven; Babcock Eileen; Bast Robert C
Project Zero Delay: a process for accelerating the activation of cancer clinical trials.
Samanta Ajoy K; Huang Helen J; Le Xiao-Feng; Mao Weiqun; Lu Karen H; Bast Robert C; Liao Warren S-L
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Xie Xiaoming; Hsu Jennifer L; Choi Min-Gew; Xia Weiya; Yamaguchi Hirohito; Chen Chun-Te; Trinh Bon Q; Lu Zhen; Ueno Naoto T; Wolf Judith K; Bast Robert C; Hung Mien-Chie
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Robert Bast (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kurzrock Razelle; Pilat Susan; Bartolazzi Marcel; Sanders Dwana; Van Wart Hood Jill; Tucker Stanley D; Webster Kevin; Mallamaci Michael A; Strand Steven; Babcock Eileen; Bast Robert C
Project Zero Delay: a process for accelerating the activation of cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4433-40.
2009: Samanta Ajoy K; Huang Helen J; Le Xiao-Feng; Mao Weiqun; Lu Karen H; Bast Robert C; Liao Warren S-L
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Cancer 2009;115(17):3897-908.
2009: Xie Xiaoming; Hsu Jennifer L; Choi Min-Gew; Xia Weiya; Yamaguchi Hirohito; Chen Chun-Te; Trinh Bon Q; Lu Zhen; Ueno Naoto T; Wolf Judith K; Bast Robert C; Hung Mien-Chie
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
Molecular cancer therapeutics 2009;8(8):2375-82.
2009: Bast Robert C; Hennessy Bryan; Mills Gordon B
The biology of ovarian cancer: new opportunities for translation.
Nature reviews. Cancer 2009;9(6):415-28.
2008: Wei Yongkun; Xia Weiya; Zhang Zhihong; Liu Jinsong; Wang Huamin; Adsay Nazmi V; Albarracin Constance; Yu Dihua; Abbruzzese James L; Mills Gordon B; Bast Robert C; Hortobagyi Gabriel N; Hung Mien-Chie
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Molecular carcinogenesis 2008;47(9):701-6.
2008: Feng Weiwei; Marquez Rebecca T; Lu Zhen; Liu Jinsong; Lu Karen H; Issa Jean-Pierre J; Fishman David M; Yu Yinhua; Bast Robert C
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Cancer 2008;112(7):1489-502.
2007: Le Xiao-Feng; Arachchige-Don Aruni S; Mao Weiqun; Horne Mary C; Bast Robert C
Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Molecular cancer therapeutics 2007;6(11):2843-57.
2007: Bast Robert C; Thigpen J Tate; Arbuck Susan G; Basen-Engquist Karen; Burke Laurie B; Freedman Ralph; Horning Sandra J; Ozols Robert; Rustin Gordon J; Spriggs David; Wenzel Lari B; Pazdur Richard
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Gynecologic oncology 2007;107(2):173-6.
2007: Badgwell Donna; Lu Zhen; Cole Laurence; Fritsche Herbert; Atkinson Edward N; Somers Elizabeth; Allard Jeffrey; Moore Richard G; Lu Karen H; Bast Robert C
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Gynecologic oncology 2007;106(3):490-7.
2007: Yang Gong; Rosen Daniel G; Mercado-Uribe Imelda; Colacino Justin A; Mills Gordon B; Bast Robert C; Zhou Chenyi; Liu Jinsong
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells.
Carcinogenesis 2007;28(1):174-82.
2007: Badgwell Donna; Bast Robert C
Early detection of ovarian cancer.
Disease markers 2007;23(5-6):397-410.
2007: Feng Weiwei; Shen Lanlan; Wen Sijin; Rosen Daniel G; Jelinek Jaroslav; Hu Xin; Huan Shaoyi; Huang Miao; Liu Jinsong; Sahin Aysegul A; Hunt Kelly K; Bast Robert C; Shen Yu; Issa Jean-Pierre J; Yu Yinhua
Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Breast cancer research : BCR 2007;9(4):R57.
2007: Bast Robert C; Brewer Molly; Zou Changping; Hernandez Mary A; Daley Mary; Ozols Robert; Lu Karen; Lu Zhen; Badgwell Donna; Mills Gordon B; Skates Steven; Zhang Zhen; Chan Dan; Lokshin Anna; Yu Yinhua
Prevention and early detection of ovarian cancer: mission impossible?
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;174():91-100.
2007: Brewer Molly; Ranger-Moore James; Satterfield William; Hao Zengping; Wang Jian; Brewer Emily; Wharton J Taylor; Bast Robert; Zou Changping
Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer.
Frontiers in bioscience : a journal and virtual library 2007;12():2260-8.
2006: Rosen Daniel G; Mercado-Uribe Imelda; Yang Gong; Bast Robert C; Amin Hesham M; Lai Raymond; Liu Jinsong
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Cancer 2006;107(11):2730-40.
2006: Wen X-F; Yang G; Mao W; Thornton A; Liu J; Bast R C; Le X-F
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
Oncogene 2006;25(52):6986-96.
2006: Yang Gong; Rosen Daniel G; Zhang Zhihong; Bast Robert C; Mills Gordon B; Colacino Justin A; Mercado-Uribe Imelda; Liu Jinsong
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(44):16472-7.
2006: Fu S; Kavanagh J J; Hu W; Bast R C
Clinical application of oxaliplatin in epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(5):1717-32.
2006: Brewer Molly; Kirkpatrick Nathaniel D; Wharton J Taylor; Wang Jian; Hatch Kenneth; Auersperg Nelly; Utzinger Urs; Gershenson David; Bast Robert; Zou Changping
4-HPR modulates gene expression in ovarian cells.
International journal of cancer. Journal international du cancer 2006;119(5):1005-13.
2006: Le Xiao-Feng; Bedrosian Isabelle; Mao Weiqun; Murray Mollianne; Lu Zhen; Keyomarsi Khandan; Lee Mong-Hong; Zhao Jiyong; Bast Robert C
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Cell cycle (Georgetown, Tex.) 2006;5(15):1654-61.
2006: Lu Zhen; Luo Robert Z; Peng Hongqi; Rosen Daniel G; Atkinson E Neely; Warneke Carla; Huang Maosheng; Nishmoto Arata; Liu Jinsong; Liao Warren S-L; Yu Yinhua; Bast Robert C
Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2404-13.
2006: Fu Siqing; Hu Wei; Kavanagh John J; Bast Robert C
Targeting Aurora kinases in ovarian cancer.
Expert opinion on therapeutic targets 2006;10(1):77-85.
2005: Bast R C; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly K A; Atkinson E N; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
New tumor markers: CA125 and beyond.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15 Suppl 3():274-81.
2005: Rosen Daniel G; Wang Lin; Atkinson J Neeley; Yu Yinhua; Lu Karen H; Diamandis Eleftherios P; Hellstrom Ingegerd; Mok Samuel C; Liu Jinsong; Bast Robert C
Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Gynecologic oncology 2005;99(2):267-77.
2005: Marquez Rebecca T; Baggerly Keith A; Patterson Andrea P; Liu Jinsong; Broaddus Russell; Frumovitz Michael; Atkinson Edward N; Smith David I; Hartmann Lynn; Fishman David; Berchuck Andrew; Whitaker Regina; Gershenson David M; Mills Gordon B; Bast Robert C; Lu Karen H
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6116-26.
2005: Bast Robert C; Lilja Hans; Urban Nicole; Rimm David L; Fritsche Herbert; Gray Joe; Veltri Robert; Klee George; Allen Andrew; Kim Nam; Gutman Steven; Rubin Mark A; Hruszkewycz Andrew
Translational crossroads for biomarkers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6103-8.
2005: Nishimoto Arata; Yu Yinhua; Lu Zhen; Mao Xiang; Ren Zhiyong; Watowich Stephanie S; Mills Gordon B; Liao Warren S-L; Chen Xiaomin; Bast Robert C; Luo Robert Z
A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
Cancer research 2005;65(15):6701-10.
2005: Brewer Molly; Wharton J Taylor; Wang Jian; McWatters Amanda; Auersperg Nelly; Gershenson David; Bast Robert; Zou Changping
In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Gynecologic oncology 2005;98(2):182-92.
2005: Hartmann Lynn C; Lu Karen H; Linette Gerald P; Cliby William A; Kalli Kimberly R; Gershenson David; Bast Robert C; Stec James; Iartchouk Natalia; Smith David I; Ross Jeffrey S; Hoersch Sebastian; Shridhar Viji; Lillie James; Kaufmann Scott H; Clark Edwin A; Damokosh Andrew I
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2149-55.
2005: Rosen Daniel G; Yang Gong; Cai Kathy Qi; Bast Robert C; Gershenson David M; Silva Elvio G; Liu Jinsong
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):632-7.
2005: Le Xiao-Feng; Pruefer Franz; Bast Robert C
HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
Cell cycle (Georgetown, Tex.) 2005;4(1):87-95.
2005: Le Xiao-Feng; Lammayot Amy; Gold David; Lu Yiling; Mao Weiqun; Chang Teresa; Patel Adarsh; Mills Gordon B; Bast Robert C
Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling.
The Journal of biological chemistry 2005;280(3):2092-104.
2004: Rosen Daniel G; Wang Lin; Jain Ajay N; Lu Karen H; Luo Robert Z; Yu Yinhua; Liu Jinsong; Bast Robert C
Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6559-66.
2004: Donato M L; Aleman A; Champlin R E; Saliba R M; Wharton J T; Burke T W; Bodurka D C; Bevers M W; Levenback C F; Wolf J K; Bast R C; Freedman R S; Ippoliti C; Brewer M; Gajewski J L; Gershenson D M
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.
Bone marrow transplantation 2004;33(12):1219-24.
2004: Lu Karen H; Patterson Andrea P; Wang Lin; Marquez Rebecca T; Atkinson Edward N; Baggerly Keith A; Ramoth Lance R; Rosen Daniel G; Liu Jinsong; Hellstrom Ingegerd; Smith David; Hartmann Lynn; Fishman David; Berchuck Andrew; Schmandt Rosemarie; Whitaker Regina; Gershenson David M; Mills Gordon B; Bast Robert C
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3291-300.
2004: Liu Jinsong; Yang Gong; Thompson-Lanza Jennifer A; Glassman Armand; Hayes Kimberly; Patterson Andrea; Marquez Rebecca T; Auersperg Nelly; Yu Yinhua; Hahn William C; Mills Gordon B; Bast Robert C
A genetically defined model for human ovarian cancer.
Cancer research 2004;64(5):1655-63.
2004: Fang Xianjun; Yu Shuangxing; Bast Robert C; Liu Shuying; Xu Hong-Ji; Hu Shi-Xue; LaPushin Ruth; Claret Francois X; Aggarwal Bharat B; Lu Yiling; Mills Gordon B
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.
The Journal of biological chemistry 2004;279(10):9653-61.
2004: Samanta Ajoy K; Huang Helen J; Bast Robert C; Liao Warren S-L
Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
The Journal of biological chemistry 2004;279(9):7576-83.
2004: Yang Gong; Cai Kathy Qi; Thompson-Lanza Jennifer A; Bast Robert C; Liu Jinsong
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
The Journal of biological chemistry 2004;279(6):4339-45.
2004: Pusztai Lajos; Krishnamurti Savitri; Perez Cardona Jorge; Sneige Nour; Esteva Francisco J; Volchenok Marina; Breitenfelder Patricia; Kau Shu-Wan; Takayama Shin; Krajewski Stanislaw; Reed John C; Bast Robert C; Hortobagyi Gabriel N
Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer.
Cancer investigation 2004;22(2):248-56.
2003: See H T; Kavanagh J J; Hu W; Bast R C
Targeted therapy for epithelial ovarian cancer: current status and future prospects.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(6):701-34.
2003: Mills Gordon B; Kohn Elise; Lu Yiling; Eder Astrid; Fang Xianjun; Wang Hongwei; Bast Robert C; Gray Joe; Jaffe Robert; Hortobagyi Gabriel
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Seminars in oncology 2003;30(5 Suppl 16):93-104.
2003: Wang Lin; Hoque Ashraful; Luo Robert Z; Yuan Jiuhong; Lu Zhen; Nishimoto Arata; Liu Jinsong; Sahin Aysegul A; Lippman Scott M; Bast Robert C; Yu Yinhua
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3660-6.
2003: Tanyi Janos L; Hasegawa Yutaka; Lapushin Ruth; Morris Andrew J; Wolf Judith K; Berchuck Andrew; Lu Karen; Smith David I; Kalli Kimberly; Hartmann Lynn C; McCune Karen; Fishman David; Broaddus Russell; Cheng Kwai W; Atkinson Edward N; Yamal Jose M; Bast Robert C; Felix Edward A; Newman Robert A; Mills Gordon B
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3534-45.
2003: Fujii Satoshi; Luo Robert Z; Yuan Jiuhong; Kadota Mitsutaka; Oshimura Mitsuo; Dent Sharon R; Kondo Yutaka; Issa Jean-Pierre J; Bast Robert C; Yu Yinhua
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.
Human molecular genetics 2003;12(15):1791-800.
2003: Yuan Jiuhong; Luo Robert Z; Fujii Satoshi; Wang Lin; Hu Wei; Andreeff Michael; Pan Yong; Kadota Mitsutaka; Oshimura Mitsuo; Sahin Aysegul A; Issa Jean-Pierre; Bast Robert C; Yu Yinhua
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Cancer research 2003;63(14):4174-80.
2003: Nakamori Mikihito; Fu Xinping; Meng Feng; Jin Aiwu; Tao Lihua; Bast Robert C; Zhang Xiaoliu
Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2727-33.
2003: Shvartsman Hyun S; Lu Karen H; Lee John; Lillie Jim; Deavers Michael T; Clifford Stephanie; Wolf Judith K; Mills Gordon B; Bast Robert C; Gershenson David M; Schmandt Rosemarie
Overexpression of kallikrein 10 in epithelial ovarian carcinomas.
Gynecologic oncology 2003;90(1):44-50.
2003: Le Xiao-Feng; Claret Francois-Xavier; Lammayot Amy; Tian Ling; Deshpande Deepa; LaPushin Ruth; Tari Ana M; Bast Robert C
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.
The Journal of biological chemistry 2003;278(26):23441-50.
2003: Luo Robert Z; Fang Xianjun; Marquez Rebecca; Liu Shu-Ying; Mills Gordon B; Liao Warren S-L; Yu Yinhua; Bast Robert C
ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers.
Oncogene 2003;22(19):2897-909.
2003: Bast Robert C
Status of tumor markers in ovarian cancer screening.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):200s-205s.
2003: Yu Yinhua; Fujii Satoshi; Yuan Jiuhong; Luo Robert Z; Wang Lin; Bao Jiaju; Kadota Mitsutaka; Oshimura Mitsuo; Dent Sharon R; Issa Jean-Pierre; Bast Robert C
Epigenetic regulation of ARHI in breast and ovarian cancer cells.
Annals of the New York Academy of Sciences 2003;983():268-77.
2003: Verschraegen Claire F; Hu Wei; Du Yu; Mendoza John; Early Janet; Deavers Michael; Freedman Ralph S; Bast Robert C; Kudelka Andrzej P; Kavanagh John J; Giovanella Beppino C
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):845-52.
2003: Mills Gordon B; Fang Xianjun; Lu Yiling; Hasegawa Yutaka; Eder Astrid; Tanyi Janos; Tabassam Fazad Haq; Mao Muling; Wang Hongwei; Cheng Kwai Wa; Nakayama Yasuhisa; Kuo Wenlin; Erickson Jim; Gershenson David; Kohn Elise C; Jaffe Robert; Bast Robert C; Gray Joe
Specific keynote: molecular therapeutics in ovarian cancer.
Gynecologic oncology 2003;88(1 Pt 2):S88-92; discussion S93-6.
2003: Bast Robert C; Mills Gordon B
General keynote: molecular therapeutics and pharmocogenomics.
Gynecologic oncology 2003;88(1 Pt 2):S84-7; discussion S93-6.
2003: Le Xiao-Feng; Hittelman Walter N; Liu Jiaxin; McWatters Amanda; Li Chun; Mills Gordon B; Bast Robert C
Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis.
Oncogene 2003;22(4):484-97.
2003: Brewer Molly A; Johnson Karen; Follen Michele; Gershenson David; Bast Robert
Prevention of ovarian cancer: intraepithelial neoplasia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):20-30.
2003: Wiener Jon R; Windham T Christopher; Estrella Veronica C; Parikh Nila U; Thall Peter F; Deavers Michael T; Bast Robert C; Mills Gordon B; Gallick Gary E
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
Gynecologic oncology 2003;88(1):73-9.
2002: Bao Jia-Ju; Le Xiao-Feng; Wang Rui-Yu; Yuan Jiuhong; Wang Lin; Atkinson Edward N; LaPushin Ruth; Andreeff Michael; Fang Bingliang; Yu Yinhua; Bast Robert C
Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway.
Cancer research 2002;62(24):7264-72.
2002: Le X-F; Varela C R; Bast R C
Heregulin-induced apoptosis.
Apoptosis : an international journal on programmed cell death 2002;7(6):483-91.
2002: Brewer Molly; Utzinger Urs; Li Yang; Atkinson E Neely; Satterfield William; Auersperg Nelly; Richards-Kortum Rebecca; Follen Michele; Bast Robert
Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents.
Journal of biomedical optics 2002;7(1):20-6.
2002: Bast Robert C; Urban Nicole; Shridhar Viji; Smith David; Zhang Zhen; Skates Steven; Lu Karen; Liu Jinsong; Fishman David; Mills Gordon
Early detection of ovarian cancer: promise and reality.
Cancer treatment and research 2002;107():61-97.
2001: Le X F; Marcelli M; McWatters A; Nan B; Mills G B; O'Brian C A; Bast R C
Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
Oncogene 2001;20(57):8258-69.
2001: Donato M L; Gershenson D M; Wharton J T; Ippoliti C M; Aleman A S; Bodurka-Bevers D; Bevers M W; Burke T W; Levenback C F; Wolf J K; Freedman R S; Bast R C; Gajewski J L; Champlin R E
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Gynecologic oncology 2001;82(3):420-6.
2001: Brewer M; Utzinger U; Satterfield W; Hill L; Gershenson D; Bast R; Wharton J T; Richards-Kortum R; Follen M
Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(8):889-93.
2001: Shridhar V; Lee J; Pandita A; Iturria S; Avula R; Staub J; Morrissey M; Calhoun E; Sen A; Kalli K; Keeney G; Roche P; Cliby W; Lu K; Schmandt R; Mills G B; Bast R C; James C D; Couch F J; Hartmann L C; Lillie J; Smith D I
Genetic analysis of early- versus late-stage ovarian tumors.
Cancer research 2001;61(15):5895-904.
2001: Luo R Z; Peng H; Xu F; Bao J; Pang Y; Pershad R; Issa J P; Liao W S; Bast R C; Yu Y
Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI.
Biochimica et biophysica acta 2001;1519(3):216-22.
2001: Rivera E; Valero V; Syrewicz L; Rahman Z; Esteva F J; Theriault R L; Rosales M M; Booser D; Murray J L; Bast R C; Hortobagyi G N;
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1716-22.
2001: Rodriguez G C; Haisley C; Hurteau J; Moser T L; Whitaker R; Bast R C; Stack M S
Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta.
Gynecologic oncology 2001;80(2):245-53.
2001: Schmidt M; McWatters A; White R A; Groner B; Wels W; Fan Z; Bast R C
Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
Gynecologic oncology 2001;80(2):145-55.
2001: Brewer M; Utzinger U; Silva E; Gershenson D; Bast R C; Follen M; Richards-Kortum R
Fluorescence spectroscopy for in vivo characterization of ovarian tissue.
Lasers in surgery and medicine 2001;29(2):128-35.
2001: Ibrahim N K; Valero V; Rahman Z; Theriault R L; Walters R S; Buzdar A U; Booser D J; Holmes F A; Murray J L; Willey J; Bast R; Hortobagyi G N
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Cancer investigation 2001;19(5):459-66.
2000: Kruzelock R P; Cuevas B D; Wiener J R; Xu F J; Yu Y; Cabeza-Arvelaiz Y; Pershouse M; Lovell M M; Killary A M; Mills G B; Bast R C
Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer.
Oncogene 2000;19(54):6277-85.
2000: Mao M; Fang X; Lu Y; Lapushin R; Bast R C; Mills G B
Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells.
The Biochemical journal 2000;352 Pt 2():475-82.
2000: Fang X; Yu S; LaPushin R; Lu Y; Furui T; Penn L Z; Stokoe D; Erickson J R; Bast R C; Mills G B
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase.
The Biochemical journal 2000;352 Pt 1():135-43.
2000: Fang X; Yu S X; Lu Y; Bast R C; Woodgett J R; Mills G B
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(22):11960-5.
2000: Xu F; Xia W; Luo R Z; Peng H; Zhao S; Dai J; Long Y; Zou L; Le W; Liu J; Parlow A F; Hung M C; Bast R C; Yu Y
The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice.
Cancer research 2000;60(17):4913-20.
2000: Xu F; Leadon S A; Yu Y; Boyer C M; O'Briant K; Ward K; McWatters A; Zhao X; Bae D S; DeSombre K; Zalutsky M R; Bast R C
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3334-41.
2000: Le X F; Vadlamudi R; McWatters A; Bae D S; Mills G B; Kumar R; Bast R C
Differential signaling by an anti-p185(HER2) antibody and heregulin.
Cancer research 2000;60(13):3522-31.
2000: Donato M L; Gershenson D; Ippoliti C; Wharton J T; Bast R C; Aleman A; Anderlini P; Gajewski J G; Giralt S; Molldrem J; Ueno N; Lauppe J; Korbling M; Boyer J; Bodurka-Bevers D; Bevers M; Burke T; Freedman R; Levenback C; Wolf J; Champlin R E
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Bone marrow transplantation 2000;25(11):1137-40.
2000: Peng H; Xu F; Pershad R; Hunt K K; Frazier M L; Berchuck A; Gray J W; Hogg D; Bast R C; Yu Y
ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.
International journal of cancer. Journal international du cancer 2000;86(5):690-4.
2000: Le X F; McWatters A; Wiener J; Wu J Y; Mills G B; Bast R C
Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):260-70.
1999: Furui T; LaPushin R; Mao M; Khan H; Watt S R; Watt M A; Lu Y; Fang X; Tsutsui S; Siddik Z H; Bast R C; Mills G B
Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4308-18.
1999: Gershenson D M; Deavers M; Diaz S; Tortolero-Luna G; Miller B E; Bast R C; Mills G B; Silva E G
Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4053-8.
1999: Fang X; Yu S; Eder A; Mao M; Bast R C; Boyd D; Mills G B
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway.
Oncogene 1999;18(48):6635-40.
1999: Pustilnik T B; Estrella V; Wiener J R; Mao M; Eder A; Watt M A; Bast R C; Mills G B
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3704-10.
1999: Xu F; Yu Y; Le X F; Boyer C; Mills G B; Bast R C
The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3653-60.
1999: Wolf J K; Mills G B; Bazzet L; Bast R C; Roth J A; Gershenson D M
Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
Gynecologic oncology 1999;75(2):261-6.
1999: Zalutsky M R; Xu F J; Yu Y; Foulon C F; Zhao X G; Slade S K; Affleck D J; Bast R C
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
Nuclear medicine and biology 1999;26(7):781-90.
1999: Ibrahim N K; Rahman Z; Valero V; Willey J; Theriault R L; Buzdar A U; Murray J L; Bast R; Hortobagyi G N
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Cancer 1999;86(7):1251-7.
1999: Baile W F; Kudelka A P; Beale E A; Glober G A; Myers E G; Greisinger A J; Bast R C; Goldstein M G; Novack D; Lenzi R
Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness.
Cancer 1999;86(5):887-97.
1999: Wiener J R; Nakano K; Kruzelock R P; Bucana C D; Bast R C; Gallick G E
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(8):2164-70.
1999: Boyer C M; Pusztai L; Wiener J R; Xu F J; Dean G S; Bast B S; O'Briant K C; Greenwald M; DeSombre K A; Bast R C
Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
International journal of cancer. Journal international du cancer 1999;82(4):525-31.
1999: Zhang Z; Barnhill S D; Zhang H; Xu F; Yu Y; Jacobs I; Woolas R P; Berchuck A; Madyastha K R; Bast R C
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Gynecologic oncology 1999;73(1):56-61.
1999: Hagopian G S; Mills G B; Khokhar A R; Bast R C; Siddik Z H
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):655-63.
1999: Yu Y; Xu F; Peng H; Fang X; Zhao S; Li Y; Cuevas B; Kuo W L; Gray J W; Siciliano M; Mills G B; Bast R C
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(1):214-9.
1998: Bast R C; Xu F J; Yu Y H; Barnhill S; Zhang Z; Mills G B
CA 125: the past and the future.
The International journal of biological markers 1998;13(4):179-87.
1998: Dean G S; Pusztai L; Xu F J; O'Briant K; DeSombre K; Conaway M; Boyer C M; Mendelsohn J; Bast R C
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2545-50.
1998: Gershenson D M; Burke T W; Morris M; Bast R C; Guaspari A; Hohneker J; Wharton J T
A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
Gynecologic oncology 1998;70(3):404-9.
1998: Bast R C; Pusztai L; Kerns B J; MacDonald J A; Jordan P; Daly L; Boyer C M; Mendelsohn J; Berchuck A
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.
Hybridoma 1998;17(4):313-21.
1998: Martell R E; Xu F J; Davis W Z; Anselmino L; Yu Y H; Daly L; Bast R C
OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders.
The International journal of biological markers 1998;13(3):145-9.
1998: Boente M P; Berchuck A; Whitaker R S; Kalén A; Xu F J; Clarke-Pearson D L; Bell R M; Bast R C
Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines.
Gynecologic oncology 1998;70(1):49-55.
1998: Patton S E; Martin M L; Nelsen L L; Fang X; Mills G B; Bast R C; Ostrowski M C
Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.
Cancer research 1998;58(10):2253-9.
1998: Fang X; Jin X; Xu H J; Liu L; Peng H Q; Hogg D; Roth J A; Yu Y; Xu F; Bast R C; Mills G B
Expression of p16 induces transcriptional downregulation of the RB gene.
Oncogene 1998;16(1):1-8.
1997: Bast R C
Summary of the first Emil J Freireich symposium.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2708-10.
1997: Xu H J; Zhou Y; Ji W; Perng G S; Kruzelock R; Kong C T; Bast R C; Mills G B; Li J; Hu S X
Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition.
Oncogene 1997;15(21):2589-96.
1997: Xu F J; Stack S; Boyer C; O'Briant K; Whitaker R; Mills G B; Yu Y H; Bast R C
Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1629-34.
1997: Xu F J; Yu Y H; Bae D S; Zhao X G; Slade S K; Boyer C M; Bast R C; Zalutsky M R
Radioiodinated antibody targeting of the HER-2/neu oncoprotein.
Nuclear medicine and biology 1997;24(5):451-9.
1997: Vredenburgh J J; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros W P; Peters W P; Bast R C
The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1997;3(2):91-7.
1997: Fang X; Gibson S; Flowers M; Furui T; Bast R C; Mills G B
Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity.
The Journal of biological chemistry 1997;272(21):13683-9.
1996: Young T N; Rodriguez G C; Rinehart A R; Bast R C; Pizzo S V; Stack M S
Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.
Gynecologic oncology 1996;62(1):89-99.
1996: van Haaften-Day C; Russell P; Boyer C M; Kerns B J; Wiener J R; Jensen D N; Bast R C; Hacker N F
Expression of cell regulatory proteins in ovarian borderline tumors.
Cancer 1996;77(10):2092-8.
1996: Olt G; Soper J; Ramakrishnan S; Xu F; Berchuck A; Clarke-Pearson D; Dodge R; Bast R C
Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer.
American journal of obstetrics and gynecology 1996;174(4):1316-9.
1996: Vredenburgh J J; Silva O; Tyer C; DeSombre K; Abou-Ghalia A; Cook M; Layfield L; Peters W P; Bast R C
A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow.
Journal of hematotherapy 1996;5(1):57-62.
1996: Tyer C L; Vredenburgh J J; Heimer M; Peters W P; Bast R C
Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):81-6.
1995: Vredenburgh J J; Peters W P; Rosner G; DeSombre K; Johnston W W; Kamel A; Wu K; Bast R C
Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy.
Bone marrow transplantation 1995;16(6):815-21.
1995: Hurteau J A; Woolas R P; Jacobs I J; Oram D C; Kurman C C; Rubin L A; Nelson D L; Berchuck A; Bast R C; Mills G B
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Cancer 1995;76(9):1615-20.
1995: Skates S J; Xu F J; Yu Y H; Sjövall K; Einhorn N; Chang Y; Bast R C; Knapp R C
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.
Cancer 1995;76(10 Suppl):2004-10.
1995: Xu F; Yu Y; Bast R C; Cornélissen G; Fujii S; Takagi M; O'Brien T; Halberg F
Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130.
In vivo (Athens, Greece) 1995;9(4):407-12.
1995: Havrilesky L J; Hurteau J A; Whitaker R S; Elbendary A; Wu S; Rodriguez G C; Bast R C; Berchuck A
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
Cancer research 1995;55(4):944-8.
1995: Bast R C; Boyer C M; Xu F J; Wiener J; Dabel R; Woolas R; Jacobs I; Berchuck A
Molecular approaches to prevention and detection of epithelial ovarian cancer.
Journal of cellular biochemistry. Supplement 1995;23():219-22.
1994: Bast R C
Clinical and laboratory directions for ovarian cancer research.
Gynecologic oncology 1994;55(3 Pt 2):S164-7.
1994: Elbendary A; Berchuck A; Davis P; Havrilesky L; Bast R C; Iglehart J D; Marks J R
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(12):1301-7.
1994: Xu F J; Boyer C M; Bae D S; Wu S; Greenwald M; O'Briant K; Yu Y H; Mills G B; Bast R C
The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
International journal of cancer. Journal international du cancer 1994;59(2):242-7.
1994: Berchuck A; Elbendary A; Havrilesky L; Rodriguez G C; Bast R C
Pathogenesis of ovarian cancers.
Journal of the Society for Gynecologic Investigation 1994;1(3):181-90.
1994: Hurteau J; Rodriguez G C; Whitaker R S; Shah S; Mills G; Bast R C; Berchuck A
Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.
Cancer 1994;74(1):93-9.
1994: Young T N; Rodriguez G C; Moser T L; Bast R C; Pizzo S V; Stack M S
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
American journal of obstetrics and gynecology 1994;170(5 Pt 1):1285-96.
1994: Lukes A S; Kohler M F; Pieper C F; Kerns B J; Bentley R; Rodriguez G C; Soper J T; Clarke-Pearson D L; Bast R C; Berchuck A
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Cancer 1994;73(9):2380-5.
1994: Wu S; Meeker W A; Wiener J R; Berchuck A; Bast R C; Boyer C M
Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha.
Gynecologic oncology 1994;53(1):59-63.
1994: Wiener J R; Hurteau J A; Kerns B J; Whitaker R S; Conaway M R; Berchuck A; Bast R C
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
American journal of obstetrics and gynecology 1994;170(4):1177-83.
1994: Wiener J R; Kerns B J; Harvey E L; Conaway M R; Iglehart J D; Berchuck A; Bast R C
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
Journal of the National Cancer Institute 1994;86(5):372-8.
1994: Kerns B J; Jordan P A; Faerman L L; Berchuck A; Bast R C; Layfield L J
Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis.
American journal of clinical pathology 1994;101(2):192-7.
1994: Moser T L; Young T N; Rodriguez G C; Pizzo S V; Bast R C; Stack M S
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
International journal of cancer. Journal international du cancer 1994;56(4):552-9.
1994: Berchuck A; Kohler M F; Hopkins M P; Humphrey P A; Robboy S J; Rodriguez G C; Soper J T; Clarke-Pearson D L; Bast R C
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Gynecologic oncology 1994;52(2):232-6.
1994: Berchuck A; Kohler M F; Marks J R; Wiseman R; Boyd J; Bast R C
The p53 tumor suppressor gene frequently is altered in gynecologic cancers.
American journal of obstetrics and gynecology 1994;170(1 Pt 1):246-52.
1994: Liu F S; Kohler M F; Marks J R; Bast R C; Boyd J; Berchuck A
Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Obstetrics and gynecology 1994;83(1):118-24.
1994: Bast R C; Xu F; Yu Y; Crews J; Argon Y; Maier L; Lidor Y; Berchuck A; Boyer C M
Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
Immunology series 1994;61():23-30.
1993: Woolas R P; Xu F J; Jacobs I J; Yu Y H; Daly L; Berchuck A; Soper J T; Clarke-Pearson D L; Oram D H; Bast R C
Elevation of multiple serum markers in patients with stage I ovarian cancer.
Journal of the National Cancer Institute 1993;85(21):1748-51.
1993: Lidor Y J; O'Briant K C; Xu F J; Hamilton T C; Ozols R F; Bast R C
Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.
The Journal of clinical investigation 1993;92(5):2440-7.
1993: Bast R C
Perspectives on the future of cancer markers.
Clinical chemistry 1993;39(11 Pt 2):2444-51.
1993: Kohler M F; Nishii H; Humphrey P A; Saski H; Marks J; Bast R C; Clarke-Pearson D L; Boyd J; Berchuck A
Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias.
American journal of obstetrics and gynecology 1993;169(3):690-4.
1993: Kohler M F; Marks J R; Wiseman R W; Jacobs I J; Davidoff A M; Clarke-Pearson D L; Soper J T; Bast R C; Berchuck A
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
Journal of the National Cancer Institute 1993;85(18):1513-9.
1993: Boente M P; Hurteau J; Rodriguez G C; Bast R C; Berchuck A
The biology of ovarian cancer.
Current opinion in oncology 1993;5(5):900-7.
1993: Lidor Y J; Xu F J; Martínez-Maza O; Olt G J; Marks J R; Berchuck A; Ramakrishnan S; Berek J S; Bast R C
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells.
Experimental cell research 1993;207(2):332-9.
1993: Peters W P; Ross M; Vredenburgh J J; Meisenberg B; Marks L B; Winer E; Kurtzberg J; Bast R C; Jones R; Shpall E
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1132-43.
1993: Jordan P A; Kerns B J; Pence J C; Kohler M F; Bast R C; Kinney R B; Berchuck A
Determination of proliferation index in advanced ovarian cancer using quantitative image analysis.
American journal of clinical pathology 1993;99(6):736-40.
1993: McKenzie S J; DeSombre K A; Bast B S; Hollis D R; Whitaker R S; Berchuck A; Boyer C M; Bast R C
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
Cancer 1993;71(12):3942-6.
1993: Kohler M F; Kerns B J; Humphrey P A; Marks J R; Bast R C; Berchuck A
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Obstetrics and gynecology 1993;81(5 ( Pt 1)):643-50.
1993: Wu S; Boyer C M; Whitaker R S; Berchuck A; Wiener J R; Weinberg J B; Bast R C
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
Cancer research 1993;53(8):1939-44.
1993: Bast R C; Boyer C M; Jacobs I; Xu F J; Wu S; Wiener J; Kohler M; Berchuck A
Cell growth regulation in epithelial ovarian cancer.
Cancer 1993;71(4 Suppl):1597-601.
1993: Xu F; Lupu R; Rodriguez G C; Whitaker R S; Boente M P; Berchuck A; Yu Y; DeSombre K A; Boyer C M; Bast R C
Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
International journal of cancer. Journal international du cancer 1993;53(3):401-8.
1993: Berchuck A; Kohler M F; Boente M P; Rodriguez G C; Whitaker R S; Bast R C
Growth regulation and transformation of ovarian epithelium.
Cancer 1993;71(2 Suppl):545-51.
1993: Rodríguez G C; Boente M P; Berchuck A; Whitaker R S; O'Briant K C; Xu F; Bast R C
The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines.
American journal of obstetrics and gynecology 1993;168(1 Pt 1):228-32.
1992: Jacobs I J; Kohler M F; Wiseman R W; Marks J R; Whitaker R; Kerns B A; Humphrey P; Berchuck A; Ponder B A; Bast R C
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
Journal of the National Cancer Institute 1992;84(23):1793-8.
1992: Boente M P; Berchuck A; Rodriguez G C; Davidoff A; Whitaker R; Xu F J; Marks J; Clarke-Pearson D L; Bast R C
The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells.
American journal of obstetrics and gynecology 1992;167(6):1877-82.
1992: Wiener J R; Berchuck A; Bast R C
Biology and therapy with biologic agents in gynecologic cancer.
Current opinion in oncology 1992;4(5):946-54.
1992: Olt G; Berchuck A; Soisson A P; Boyer C M; Bast R C
Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.
Cancer 1992;70(8):2137-42.
1992: Berchuck A; Kohler M F; Bast R C
Oncogenes in ovarian cancer.
Hematology/oncology clinics of North America 1992;6(4):813-27.
1992: Daly L; Ferguson J; Cram G P; Hars V; George S L; McCarty K S; Bast R C
Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(7):1057-65.
1992: Kerns B J; Jordan P A; Moore M B; Humphrey P A; Berchuck A; Kohler M F; Bast R C; Iglehart J D; Marks J R
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1992;40(7):1047-51.
1992: Einhorn N; Sjövall K; Knapp R C; Hall P; Scully R E; Bast R C; Zurawski V R
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
Obstetrics and gynecology 1992;80(1):14-8.
1992: Deutsch M A; Pence J C; Kerns B J; Plate C A; Kinney R; Gooch G; Iglehart J D; Bast R C
Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody.
Cancer 1992;69(12):2894-904.
1992: Wu S; Rodabaugh K; Martinez-Maza O; Watson J M; Silberstein D S; Boyer C M; Peters W P; Weinberg J B; Berek J S; Bast R C
Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.
American journal of obstetrics and gynecology 1992;166(3):997-1007.
1992: Berchuck A; Boente M P; Bast R C
The use of tumor markers in the management of patients with gynecologic carcinomas.
Clinical obstetrics and gynecology 1992;35(1):45-54.
1992: Kohler M F; Berchuck A; Davidoff A M; Humphrey P A; Dodge R K; Iglehart J D; Soper J T; Clarke-Pearson D L; Bast R C; Marks J R
Overexpression and mutation of p53 in endometrial carcinoma.
Cancer research 1992;52(6):1622-7.
1992: Berchuck A; Rodriguez G; Olt G; Whitaker R; Boente M P; Arrick B A; Clarke-Pearson D L; Bast R C
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
American journal of obstetrics and gynecology 1992;166(2):676-84.
1992: Berchuck A; Boente M P; Kerns B J; Kinney R B; Soper J T; Clarke-Pearson D L; Bast R C; Bacus S S
Ploidy analysis of epithelial ovarian cancers using image cytometry.
Gynecologic oncology 1992;44(1):61-5.
1991: Xu F J; Ramakrishnan S; Daly L; Soper J T; Berchuck A; Clarke-Pearson D; Bast R C
Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
American journal of obstetrics and gynecology 1991;165(5 Pt 1):1356-62.
1991: Lidor Y J; Shpall E J; Peters W P; Bast R C
Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer.
International journal of cancer. Journal international du cancer 1991;49(5):704-10.
1991: Bast R C; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp R C
Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
Cancer 1991;68(8):1758-63.
1991: Maier L A; Xu F J; Hester S; Boyer C M; McKenzie S; Bruskin A M; Argon Y; Bast R C
Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.
Cancer research 1991;51(19):5361-9.
1991: O'Briant K C; Shpall E J; Houston L L; Peters W P; Bast R C
Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres.
Cancer 1991;68(6):1272-8.
1991: Marks J R; Davidoff A M; Kerns B J; Humphrey P A; Pence J C; Dodge R K; Clarke-Pearson D L; Iglehart J D; Bast R C; Berchuck A
Overexpression and mutation of p53 in epithelial ovarian cancer.
Cancer research 1991;51(11):2979-84.
1991: Jerome K R; Barnd D L; Bendt K M; Boyer C M; Taylor-Papadimitriou J; McKenzie I F; Bast R C; Finn O J
Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
Cancer research 1991;51(11):2908-16.
1991: Rodriguez G C; Berchuck A; Whitaker R S; Schlossman D; Clarke-Pearson D L; Bast R C
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.
American journal of obstetrics and gynecology 1991;164(3):745-50.
1991: Shpall E J; Bast R C; Joines W T; Jones R B; Anderson I; Johnston C; Eggleston S; Tepperberg M; Edwards S; Peters W P
Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation.
Bone marrow transplantation 1991;7(2):145-51.
1991: Berchuck A; Rodriguez G C; Kamel A; Dodge R K; Soper J T; Clarke-Pearson D L; Bast R C
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.
American journal of obstetrics and gynecology 1991;164(2):669-74.
1991: Shpall E J; Jones R B; Bast R C; Rosner G L; Vandermark R; Ross M; Affronti M L; Johnston C; Eggleston S; Tepperburg M
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):85-93.
1991: Yu Y H; Schlossman D M; Harrison C L; Rhinehardt-Clark A; Soper J T; Klug T L; Zurawski V R; Bast R C
Coexpression of different antigenic markers on moieties that bear CA 125 determinants.
Cancer research 1991;51(2):468-75.
1991: Berchuck A; Rodriguez G; Kinney R B; Soper J T; Dodge R K; Clarke-Pearson D L; Bast R C
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.
American journal of obstetrics and gynecology 1991;164(1 Pt 1):15-21.
1990: Soper J T; Berchuck A; Olt G J; Soisson A P; Clarke-Pearson D L; Bast R C
Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma.
American journal of obstetrics and gynecology 1990;163(4 Pt 1):1204-9.
1990: Hunter V J; Daly L; Helms M; Soper J T; Berchuck A; Clarke-Pearson D L; Bast R C
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
American journal of obstetrics and gynecology 1990;163(4 Pt 1):1164-7.
1990: Shpall E J; Clarke-Pearson D; Soper J T; Berchuck A; Jones R B; Bast R C; Ross M; Lidor Y; Vanacek K; Tyler T
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
Gynecologic oncology 1990;38(3):386-91.
1990: Berchuck A; Rodriguez G; Kamel A; Soper J T; Clarke-Pearson D L; Bast R C
Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.
Obstetrics and gynecology 1990;76(3 Pt 1):381-7.
1990: Olt G; Berchuck A; Bast R C
The role of tumor markers in gynecologic oncology.
Obstetrical & gynecological survey 1990;45(9):570-7.
1990: Leslie D S; Johnston W W; Daly L; Ring D B; Shpall E J; Peters W P; Bast R C
Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology.
American journal of clinical pathology 1990;94(1):8-13.
1990: Welch W R; Niloff J M; Anderson D; Battaile A; Emery S; Knapp R C; Bast R C
Antigenic heterogeneity in human ovarian cancer.
Gynecologic oncology 1990;38(1):12-6.
1990: Berchuck A; Olt G J; Soisson A P; Kamel A; Soper J T; Boyer C M; Clarke-Pearson D L; Leslie D S; Bast R C
Heterogeneity of antigen expression in advanced epithelial ovarian cancer.
American journal of obstetrics and gynecology 1990;162(4):883-8.
1990: Zurawski V R; Sjovall K; Schoenfeld D A; Broderick S F; Hall P; Bast R C; Eklund G; Mattsson B; Connor R J; Prorok P C
Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer.
Gynecologic oncology 1990;36(3):299-305.
1990: Berchuck A; Olt G J; Everitt L; Soisson A P; Bast R C; Boyer C M
The role of peptide growth factors in epithelial ovarian cancer.
Obstetrics and gynecology 1990;75(2):255-62.
1990: Soper J T; Hunter V J; Daly L; Tanner M; Creasman W T; Bast R C
Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Obstetrics and gynecology 1990;75(2):249-54.
1990: Shpall E J; Anderson I C; Bast R C; Joines W T; Jones R B; Ross M; Edwards S; Eggleston S; Johnston C; Tepperberg M
Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation.
Progress in clinical and biological research 1990;333():321-35; discussion 336.
1990: Olt G J; Berchuck A; Bast R C
Gynecologic tumor markers.
Seminars in surgical oncology 1990;6(6):305-13.
1989: Soisson A P; Berchuck A; Lessey B A; Soper J T; Clarke-Pearson D L; McCarty K S; Bast R C
Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels.
American journal of obstetrics and gynecology 1989;161(5):1258-63.
1989: Berchuck A; Soisson A P; Olt G J; Soper J T; Clarke-Pearson D L; Bast R C; McCarty K S
Epidermal growth factor receptor expression in normal and malignant endometrium.
American journal of obstetrics and gynecology 1989;161(5):1247-52.
1989: Berchuck A; Soisson A P; Soper J T; Clarke-Pearson D L; Bast R C; McCarty K S
Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues.
Archives of pathology & laboratory medicine 1989;113(10):1155-8.
1989: Anderson I C; Shpall E J; Leslie D S; Nustad K; Ugelstad J; Peters W P; Bast R C
Elimination of malignant clonogenic breast cancer cells from human bone marrow.
Cancer research 1989;49(16):4659-64.
1989: Boyer C M; Dawson D V; Neal S E; Winchell L F; Leslie D S; Ring D; Bast R C
Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines.
Cancer research 1989;49(11):2928-34.
1989: Berchuck A; Soisson A P; Clarke-Pearson D L; Soper J T; Boyer C M; Kinney R B; McCarty K S; Bast R C
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential.
Cancer research 1989;49(8):2091-5.
1989: Ramakrishnan S; Xu F J; Brandt S J; Niedel J E; Bast R C; Brown E L
Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines.
The Journal of clinical investigation 1989;83(3):921-6.
1989: Boyer C M; Borowitz M J; McCarty K S; Kinney R B; Everitt L; Dawson D V; Ring D; Bast R C
Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells.
International journal of cancer. Journal international du cancer 1989;43(1):55-60.
1989: Bast R C
Antigens associated with epithelial ovarian carcinomas.
Progress in clinical and biological research 1989;288():73-83.
1989: Zalutsky M R; Bast R C; Knapp R C
Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(4):405-11.
1989: Peters W P; Stuart A; Klotman M; Gilbert C; Jones R B; Shpall E J; Gockerman J; Bast R C; Moore J O
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.
Cancer chemotherapy and pharmacology 1989;23(6):377-83.
1988: Peters W P; Shpall E J; Jones R B; Olsen G A; Bast R C; Gockerman J P; Moore J O
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(9):1368-76.
1988: Olsen G A; Gockerman J P; Bast R C; Borowitz M; Peters W P
Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support.
Transplantation 1988;46(1):57-60.
1988: Brandt S J; Peters W P; Atwater S K; Kurtzberg J; Borowitz M J; Jones R B; Shpall E J; Bast R C; Gilbert C J; Oette D H
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.
The New England journal of medicine 1988;318(14):869-76.
1988: Zalutsky M R; Knapp R C; Bast R C
Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1988;15(4):431-7.
1988: Lidor Y; Bast R C
Serotherapy of ovarian cancer.
Natural immunity and cell growth regulation 1988;7(4):193-215.
1987: Peters W P; Henner W D; Grochow L B; Olsen G; Edwards S; Stanbuck H; Stuart A; Gockerman J; Moore J; Bast R C
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors.
Cancer research 1987;47(23):6402-6.
1987: Leoni F; Bast R C; Canevari S; Menard S; Soper J T; Colnaghi M I
Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer.
International journal of cancer. Journal international du cancer 1987;40(5):592-7.
1987: Bast R C; Hunter V; Knapp R C
Pros and cons of gynecologic tumor markers.
Cancer 1987;60(8 Suppl):1984-92.
1987: Haleem A; Kurtzberg J; Olsen G A; Rhinehardt-Clark A; Leslie D S; Ray L; Smith C A; Peters W P; Haynes B F; Bast R C
Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement.
Cancer research 1987;47(17):4608-12.
1986: Davis H M; Zurawski V R; Bast R C; Klug T L
Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.
Cancer research 1986;46(12 Pt 1):6143-8.
1986: Niloff J M; Knapp R C; Lavin P T; Malkasian G D; Berek J S; Mortel R; Whitney C; Zurawski V R; Bast R C
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer.
American journal of obstetrics and gynecology 1986;155(1):56-60.
1986: Berek J S; Knapp R C; Malkasian G D; Lavin P T; Whitney C; Niloff J M; Bast R C
CA 125 serum levels correlated with second-look operations among ovarian cancer patients.
Obstetrics and gynecology 1986;67(5):685-9.
1985: Bast R C; Siegal F P; Runowicz C; Klug T L; Zurawski V R; Schonholz D; Cohen C J; Knapp R C
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma.
Gynecologic oncology 1985;22(1):115-20.
1985: Niloff J M; Knapp R C; Jones G; Schaetzl E M; Bast R C
Recombinant leukocyte alpha interferon in advanced ovarian carcinoma.
Cancer treatment reports 1985;69(7-8):895-6.
1985: Niloff J M; Bast R C; Schaetzl E M; Knapp R C
Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.
American journal of obstetrics and gynecology 1985;151(7):981-6.
1984: Niloff J M; Knapp R C; Schaetzl E; Reynolds C; Bast R C
CA125 antigen levels in obstetric and gynecologic patients.
Obstetrics and gynecology 1984;64(5):703-7.
1984: Bast R C; Klug T L; Schaetzl E; Lavin P; Niloff J M; Greber T F; Zurawski V R; Knapp R C
Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.
American journal of obstetrics and gynecology 1984;149(5):553-9.
1984: Niloff J M; Klug T L; Schaetzl E; Zurawski V R; Knapp R C; Bast R C
Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix.
American journal of obstetrics and gynecology 1984;148(8):1057-8.
1984: Klug T L; Bast R C; Niloff J M; Knapp R C; Zurawski V R
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas.
Cancer research 1984;44(3):1048-53.
1983: Bast R C; Klug T L; St John E; Jenison E; Niloff J M; Lazarus H; Berkowitz R S; Leavitt T; Griffiths C T; Parker L; Zurawski V R; Knapp R C
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
The New England journal of medicine 1983;309(15):883-7.
1983: Bast R C; Berek J S; Obrist R; Griffiths C T; Berkowitz R S; Hacker N F; Parker L; Lagasse L D; Knapp R C
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Cancer research 1983;43(3):1395-401.
1983: Obrist R; Reilly R; Leavitt T; Knapp R C; Bast R C
Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma.
International journal of immunopharmacology 1983;5(4):307-14.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Robert Bast

Research Profile (preview)

Disorders

Anatomy

Chemicals & Drugs

Physiology

Concepts & Ideas

Procedures

Living Beings

Genes & Molecular Sequences

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Robert Bast (preview)

All Publications